Sarepta Therapeutics (SRPT)
(Delayed Data from NSDQ)
$127.21 USD
+0.11 (0.09%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $127.29 +0.08 (0.06%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth F Momentum D VGM
Cash flow Statements
Fiscal Year End for Sarepta Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -535.98 | -703.49 | -418.78 | -554.13 | -715.08 |
Depreciation/Amortization & Depletion | -1.78 | 41.86 | 38.02 | 24.73 | 22.10 |
Net Change from Assets/Liabilities | -481.09 | -39.47 | -98.17 | 554.06 | -66.88 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 517.85 | 375.75 | 35.76 | 82.81 | 303.39 |
Net Cash From Operating Activities | -500.99 | -325.35 | -443.17 | 107.47 | -456.46 |
Property & Equipment | -76.11 | -30.82 | -38.49 | -82.20 | -59.63 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | -172.56 |
Investments | -180.46 | -1,013.63 | 436.01 | -144.09 | 521.99 |
Other Investing Activities | 90.76 | -2.43 | 97.89 | 104.57 | -3.08 |
Net Cash from Investing Activities | -165.80 | -1,046.88 | 495.41 | -121.72 | 286.73 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 51.25 | 30.04 | 569.33 | 396.01 | 401.96 |
Issuance (Repayment) of Debt | 0.00 | 329.53 | 0.00 | 291.15 | 245.63 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 73.76 | -127.07 | -7.77 | -4.84 | -5.03 |
Net Cash from Financing Activities | 125.00 | 232.51 | 561.57 | 682.32 | 642.55 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -541.79 | -1,139.72 | 613.81 | 668.07 | 472.82 |
Cash at Beginning of Period | 985.80 | 2,125.52 | 1,511.71 | 843.65 | 370.83 |
Cash at End of Period | 444.01 | 985.80 | 2,125.52 | 1,511.71 | 843.65 |
Diluted Net EPS | -5.80 | -8.03 | -5.15 | -7.11 | -9.71 |
Fiscal Year End for Sarepta Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | 42.58 | 36.12 | -535.98 | -581.63 | -540.70 |
Depreciation/Amortization & Depletion | -5.40 | -3.66 | -1.78 | 0.18 | 1.85 |
Net Change from Assets/Liabilities | -374.99 | -184.57 | -481.09 | -330.80 | -176.09 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 110.67 | -89.97 | 517.85 | 465.92 | 383.30 |
Net Cash From Operating Activities | -227.13 | -242.08 | -500.99 | -446.34 | -331.63 |
Property & Equipment | -61.61 | -32.44 | -76.11 | -57.07 | -27.39 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 191.88 | 261.24 | -180.46 | -135.14 | 34.66 |
Other Investing Activities | -10.00 | -10.00 | 90.76 | 90.76 | 101.86 |
Net Cash from Investing Activities | 120.27 | 218.80 | -165.80 | -101.45 | 109.13 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 62.06 | 22.14 | 51.25 | 49.30 | 33.90 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 0.00 | 73.76 | 73.76 | 73.76 |
Net Cash from Financing Activities | 62.06 | 22.14 | 125.00 | 123.06 | 107.66 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -44.81 | -1.14 | -541.79 | -424.72 | -114.85 |
Cash at Beginning of Period | 444.01 | 444.01 | 985.80 | 985.80 | 985.80 |
Cash at End of Period | 399.20 | 442.87 | 444.01 | 561.08 | 870.95 |
Diluted Net EPS | 0.07 | 0.37 | 0.79 | -0.46 | -0.27 |